Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with a focus on neuroscience and intranasal pherine product candidates. The VTGN news feed highlights the company’s progress as it advances its nose-to-brain neurocircuitry platform for conditions such as social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
News about Vistagen frequently covers clinical trial milestones, including updates from its PALISADE Phase 3 public speaking challenge studies of fasedienol for the acute treatment of social anxiety disorder. These items may include announcements that randomized, double-blind, placebo-controlled trial phases have been completed, topline results from specific studies such as PALISADE-3, and commentary on how outcomes compare with earlier trials like PALISADE-2. The company also reports on exploratory and nonclinical data for other pherine candidates, such as PH80 for menopausal hot flashes, including findings on brain and autonomic effects and mechanistic insights presented at scientific meetings.
Investors and observers can also find corporate and governance updates in Vistagen’s news, such as board appointments, executive leadership changes, and participation in healthcare and neuropsychiatry conferences. Press releases may discuss new director appointments, additions to the executive team, and information about investor presentations and conference webcasts.
For those tracking VTGN, the news stream offers a consolidated view of clinical, scientific, and corporate developments that shape the company’s pherine pipeline and regulatory strategy. Regularly reviewing these updates can provide context on trial outcomes, regulatory designations, and Vistagen’s stated plans for its late-stage programs in mental health and women’s health.
Vistagen (Nasdaq: VTGN) reported its fiscal year 2024 financial results, showcasing significant progress in its clinical programs. The company highlighted positive results from the PALISADE-2 Phase 3 trial of fasedienol for social anxiety disorder (SAD), with PALISADE-3 initiated and PALISADE-4 set to start in 2H 2024. Additionally, itruvone for major depressive disorder (MDD) and PH80 for menopausal hot flashes showed positive Phase 1 and Phase 2A data, respectively. Financially, Vistagen's R&D expenses decreased to $20.0 million from $44.4 million, and G&A expenses slightly fell to $14.1 million from $14.7 million. The net loss was significantly reduced to $29.4 million compared to $59.2 million in the previous year. Cash and cash equivalents stood at $119.2 million as of March 31, 2024.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company focusing on psychiatric and neurological disorders, will report its fiscal year 2024 financial results on June 11, 2024.
The announcement will be made through a conference call and webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). During the call, Vistagen will provide a detailed update on its corporate activities and financial performance for the fiscal year ending March 31, 2024.
Participants can join the call using the toll-free number 1-877-407-9716 in the US, or 1-201-493-6779 internationally, with the Conference ID: 13746589. A replay will be available shortly after the call ends.
Vistagen, a late clinical-stage biopharmaceutical company focused on innovative therapies for psychiatric and neurological disorders, announced its participation in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York City.
CEO Shawn Singh will present a fireside chat on June 6 at 11:00 a.m. EST, with a webcast available on Vistagen's website. Interested investors can arrange one-on-one meetings through their Jefferies representative.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced it will present posters at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference from May 28-31, 2024, in Miami Beach, Florida.
The presentations will focus on fasedienol (PH94B) for social anxiety disorder (SAD) and itruvone (PH10) for major depressive disorder (MDD). The fasedienol poster, titled 'Results from the PALISADE-2 Phase 3 Trial,' will be presented on May 29, 2024, at 11:15 a.m. ET. The itruvone poster, titled 'Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats,' will also be presented on May 29, 2024, at 11:15 a.m. ET.
Both posters will be available on Vistagen's website from June 3, 2024.
Vistagen (Nasdaq: VTGN) will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference in New York City. CEO Shawn Singh will participate in a fireside chat on May 15. Investors can arrange one-on-one meetings through their RBC representative.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
